The FDA has granted Adapt Pharma Fast Track designation for its intranasal naloxone for the treatment of opioid overdose, the company said. Adapt Pharma licensed the product from Lightlake Therapeutics in December 2014. In the same month, Lightlake began a new trial of the drug for the opiod overdose reversal indication. Funding for the trial has been provided by the National Institute on Drug Abuse (NIDA).
Lightlake CEO Roger Crystal commented, “We are very pleased the FDA granted Fast Track designation to Adapt Pharma for the intranasal naloxone treatment to reverse opioid overdose. The decision reflects the critical need for better delivery of and access to naloxone. Too many lives have been lost by opioid overdose and we look forward to this novel technology being available to patients and bystanders in the US. We are very pleased that the team at Adapt is pushing this product forward on all fronts.”
Read the Adapt Pharma press release.
Read the Lightlake Therapeutics press release.
